Capturing unexpected benefits of research

5 June 2001

25%-40% of the sales of top-selling drugs in the UK and USA are for newindications discovered only after the drugs were launched on the market, reports the UK industry-backed Office of Health Economics.

New uses can emerge following basic science discoveries which reveal mechanisms of action or fundamental properties of an existing technology, it says. Also, "translational" research can identify new uses based on known properties and mechanisms of action, applying them to other, closely related, disorders or organ systems. Alternatively, new clinical observations can suggest new targets for existing medicines.

For example, the discovery of Helicobacter pylori's role in causing peptic ulcers has led to new treatment approaches, while serendipitous findings in early-stage clinical trials revealed the benefit of Viagra (sildenafil) in erectile dysfunction. Translational research has expanded the range of conditions to which photodynamic therapy can be applied, from the destruction of cancer to the treatment of occlusive arterial disease, and both basic science and clinical observation have contributed to new indications for beta blockers and ACE inhibitors in cardiovascular medicine.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight